Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/147097
dc.contributor.author | Molleví, David Garcia |
---|---|
dc.contributor.author | Aytés Meneses, Álvaro |
dc.contributor.author | Padullés Mosella, Laura |
dc.contributor.author | Martínez Iniesta, María |
dc.contributor.author | Baixeras, Núria |
dc.contributor.author | Salazar Soler, Ramón |
dc.contributor.author | Ramos Rubio, Emilio |
dc.contributor.author | Figueras Aloy, José, 1950- |
dc.contributor.author | Capellá, G. (Gabriel) |
dc.contributor.author | Villanueva Garatachea, Alberto |
dc.date | 2019-12-20T15:50:20Z |
dc.date | 2019-12-20T15:50:20Z |
dc.date | 2008-10-28 |
dc.date | 2019-12-20T15:50:20Z |
dc.identifier.citation | 0007-0920 |
dc.identifier.citation | 606220 |
dc.identifier.uri | http://hdl.handle.net/2445/147097 |
dc.description.abstract | Phosphatase PRL-3 has been involved in different types of cancer, especially in metastases from colorectal carcinoma (CRC). In this study, we explored both isoforms of PRL-3 as a biomarker to predict the recurrence of stage IIIB-C CRC. Overexpression of PRL-3 was investigated in primary human colorectal tumours (n=20) and hepatic metastases (n=36) xenografted in nude mice, samples characterised by absence of human non-tumoral cells, showing a high degree of expression in metastases (P=0.001). In 27 cases of matched normal colonic mucosa/primary tumour/hepatic metastases, PRL-3 overexpression occurs in primary tumours vs normal mucosa (P=0.001) and in hepatic metastases vs primary tumours (P=0.045). Besides, our results in a series of 80 stage IIIB-C CRC primary tumours showed that high levels of PRL-3 were an independent predictor of metastasis (P<0.0001; OR: 9.791) in multivariate analysis of a binary logistic regression and that PRL-3 expression tightly correlates with parameters of bad outcome. Moreover, PRL-3 expression associated with poor outcome in univariate (P<0.0001) and multivariate Cox models (hazard ratio: 3.322, 95%, confidence interval: 1.405-7.852, P=0.006). In conclusion, PRL-3 is a good marker of aggressiveness of locally advanced CRS and a promising predictor of distant metastases. Nevertheless, for prognosis purposes, it is imperative to validate the cutoff value of PRL-3 expression in a larger and consecutive series and adjuvant setting. |
dc.format | 8 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | Cancer Research UK |
dc.relation | Versió postprint del document publicat a: https://doi.org/10.1038/sj.bjc.6604747 |
dc.relation | British Journal of Cancer, 2008, vol. 99, num. 10, p. 1718-1725 |
dc.relation | https://doi.org/10.1038/sj.bjc.6604747 |
dc.rights | (c) Molleví, David Garcia et al., 2008 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Metabolisme |
dc.subject | Càncer colorectal |
dc.subject | Patologia |
dc.subject | Càncer de fetge |
dc.subject | Metabolism |
dc.subject | Colorectal cancer |
dc.subject | Pathology |
dc.subject | Liver cancer |
dc.title | PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/acceptedVersion |